Cargando…

How do BRAF(V600E) and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?

CONTEXT: The American Thyroid Association risk stratification (ATA) and the American Joint Committee on Cancer Tumor Node Metastases (TNM) predict recurrence and mortality of differentiated thyroid cancer (DTC). BRAF(V600E) and TERT promoter mutations have been shown to correlate with the histopatho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukhtar, Noha, Alhamoudi, Kheloud, Alswailem, Meshael, Alhindi, Hindi, Murugan, Avaniyapuram Kannan, Alghamdi, Balgees, Alzahrani, Ali S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582750/ https://www.ncbi.nlm.nih.gov/pubmed/37859987 http://dx.doi.org/10.3389/fendo.2023.1270796

Ejemplares similares

THU683 TERT Promoter Mutations, But Not BRAF(V600E)Mutation, Correlate With The American Thyroid Association And TNM Staging Systems And Predict Outcome Of Differentiated Thyroid Cancer
por: Mukhtar, Noha, et al.
Publicado: (2023)

Papillary Thyroid Cancer and a TERT Promotor Mutation-positive Paraganglioma in a Patient With a Germline SDHB Mutation
por: Alzahrani, Ali S, et al.
Publicado: (2022)

Case Report: Severe Gonadal Dysgenesis Causing 46,XY Disorder of Sex Development Due to a Novel NR5A1 Variant
por: Alhamoudi, Kheloud M., et al.
Publicado: (2022)

Thyroid Cancer, Neuroendocrine Tumor, Adrenal Adenoma, and Other Tumors in a Patient With a Germline PMS1 Mutation
por: Alghamdi, Balgees, et al.
Publicado: (2023)

Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2016)

SAT631 EPAS1 Mutations In Three Adjacent Nucleotides Resulting In Different Phenotypes
por: Alswailem, Meshael, et al.
Publicado: (2023)

THU614 Neurofibromatosis Type 1 Presenting With Pheochromocytoma And Severe Vascular And Hematological Manifestations Due To A Novel NF1 Mutation
por: Alobaid, Lulu Abdulaziz, et al.
Publicado: (2023)

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer
por: Zhang, Zongjing, et al.
Publicado: (2014)

GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2019)

Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2021)

SAT604 An Extensively Invasive Giant Prolactinoma Associated With CDH23 Mutation
por: Alghamdi, Balgees, et al.
Publicado: (2023)

Prospective study and proposal of an outcome predictive nomogram in a consecutive prospective series of differentiated thyroid cancer based on the new ATA risk categories and TNM
por: Sapuppo, Giulia, et al.
Publicado: (2023)

SAT613 A Novel NF1 Mutation As The Underlying Cause Of Dysmorphic Features And Acromegaly In An Atypical Case Of Neurofibromatosis Type 1
por: Alsagheir, Osamah, et al.
Publicado: (2023)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves’ disease
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2021)

SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2021)

Mechanisms of TERT Reactivation and Its Interaction with BRAF(V600E)
por: Song, Young Shin, et al.
Publicado: (2020)

Absence of somatic mutations of the mTOR gene in differentiated thyroid cancer
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2015)

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
por: Han, Ying, et al.
Publicado: (2022)

Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma
por: Albattal, Shatha, et al.
Publicado: (2019)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

MIEAP and ATG5 are tumor suppressors in a mouse model of BRAF(V600E)-positive thyroid cancer
por: Hamada, Koichiro, et al.
Publicado: (2022)

Association Between Preoperative US, Elastography Features and Prognostic Factors of Papillary Thyroid Cancer With BRAF(V600E) Mutation
por: Xu, Jun-Mei, et al.
Publicado: (2020)

Radiomic Model for Determining the Value of Elasticity and Grayscale Ultrasound Diagnoses for Predicting BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wang, Yu-guo, et al.
Publicado: (2022)

The diagnostic efficacy and inappropriate biopsy rate of ACR TI-RADS and ATA guidelines for thyroid nodules in children and adolescents
por: Li, Guanghan, et al.
Publicado: (2023)

A Novel Mutation in a Gene Causes Sclerosteosis in a Family of Mediterranean Origin
por: Ekhzaimy, Aishah A., et al.
Publicado: (2022)

Targeting BRAF(V600E) with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer
por: Nucera, Carmelo, et al.
Publicado: (2011)

Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation
por: Xu, Cheng, et al.
Publicado: (2022)

The New TNM Staging System for Thyroid Cancer and the Risk of Disease Downstaging
por: Casella, Claudio, et al.
Publicado: (2018)

Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?
por: Nucera, Carmelo, et al.
Publicado: (2012)

Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms
por: Harikrishnan, Volga, et al.
Publicado: (2021)

ATA Announcement
por: Forstag, Benjamin
Publicado: (2011)

Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Braf(v600e) Mutation: A Single Center Study of 1,207 Chinese Patients
por: Xue, Shuai, et al.
Publicado: (2019)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Liu, Rengyun, et al.
Publicado: (2018)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers
por: Wu, Yongxing, et al.
Publicado: (2021)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit
por: Censi, Simona, et al.
Publicado: (2017)

MON-533 Diffuse Sclerosing Variant Papillary Thyroid Cancer: Clinical and Histopathological Features, Mutational Profile, Management and Outcome
por: Aljomaiah, Abeer Abdulhadi, et al.
Publicado: (2020)

BRAF(V600E) Mutation-Responsive miRNA-222-3p Promotes Metastasis of Papillary Thyroid Cancer Cells via Snail-Induced EMT
por: Gao, Yuan, et al.
Publicado: (2022)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6nr0cn97a2j68k15to1cs1bhc7